The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J.
Isa R, et al. Among authors: okamoto h.
Int J Mol Sci. 2022 Mar 8;23(6):2919. doi: 10.3390/ijms23062919.
Int J Mol Sci. 2022.
PMID: 35328342
Free PMC article.